Paradigm Biopharmaceuticals Limited (ASX:PAR) has had its securities suspended from quotation with immediate effect, following ASX's determination that the company's financial condition is not adequate to warrant continued quotation, after the appointment of voluntary administrators was announced on 30 September 2026.
Key Points
- ASX suspended PAR securities from quotation immediately, effective 30 September 2026, under Listing Rule 17.3.
- ASX determined PAR's financial condition is not adequate to warrant continued quotation of its securities.
- PAR was found to be in breach of Listing Rule 12.2 following the voluntary administration appointment.
- Suspension will continue until ASX is satisfied PAR complies with the Listing Rules, including Listing Rule 12.2, and reinstatement is otherwise appropriate.
Voluntary Administration and Immediate Suspension
ASX Compliance issued the suspension notice on 30 September 2026, acting in accordance with Listing Rule 17.3. The suspension followed an announcement released on the market announcements platform on Wednesday, 30 September 2026, disclosing the appointment of voluntary administrators to Paradigm Biopharmaceuticals Limited. ASX determined, having regard to that announcement, that the company's financial condition was not adequate to warrant the continued quotation of its securities on the exchange.
Breach of ASX Listing Rule 12.2
As a result of ASX's assessment of the company's financial condition, Paradigm Biopharmaceuticals was found to be in breach of ASX Listing Rule 12.2. That listing rule relates to the financial condition required for a company's securities to remain quoted on the ASX. The filing states the determination was made directly in connection with the voluntary administration appointment disclosed on the same date, 30 September 2026, by Paradigm Biopharmaceuticals.
Conditions Required for Reinstatement to Quotation
According to the filing issued by ASX Compliance, the suspension of PAR securities will continue until ASX is satisfied that Paradigm Biopharmaceuticals is in compliance with the Listing Rules, including specifically Listing Rule 12.2, and that it is otherwise appropriate for the company's securities to be reinstated to quotation. No specific timeframe or conditions beyond compliance with the Listing Rules were disclosed in the filing regarding the pathway to reinstatement.





Please wait processing your request...